Xu A et al28 showed that EGFR-TKI targeted therapy applied to patients with advanced EGFR mutant NSCLC can downregulate the levels of CEA, CYFRA21-1 and MMP-9, effectively inhibit angiogenesis and enhance the immune function of patients. Here, MMP9 is linked to non-small cell lung carcinoma.